HCPLive Five at ASRS 2024

A meeting spot to discuss the latest trial data and technical updates in ophthalmology, retina specialists gathered to attend the American Society of Retina Specialists (ASRS) 42nd Annual Meeting in Stockholm, Sweden.

As part of our meeting coverage, the HCPLive Ophthalmology editorial team was on-site in Stockholm conducting interviews and live coverage. In this edition of the HCPLive Five, we recap our video interviews related to coverage of ASRS 2024, including videos centered around new gene therapy data, interim results on a tyrosine kinase inhibitor (TKI) implant, and new 4-year data on the utility of dual inhibition with faricimab.

#5: Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD

Subretinal delivery of investigational ABBV-RGX-314 gene therapy provided by the NAVXpress bioreactor platform was well-tolerated with a similar clinical profile to the adherent cell culture process for neovascular age-related macular degeneration (nAMD), according to Phase II pharmacodynamic study data.

In this clip, Wood discusses the promise of gene therapy for lowering patient treatment burden in retina.

#4 Dilsher Dhoot, MD: Interim Results on OTX-TKI for NPDR in HELIOS

Interim data from the Phase 1 HELIOS trial demonstrated the tolerability and efficacy of sustained-release Axitinib Implant (OTX-TKI) for moderately severe to severe non-proliferative diabetic retinopathy (NPDR) at 48 weeks.

In this clip, Dhoot describes the potential utility of tyrosine kinase inhibitors (TKIs) for retinal diseases.

#3 Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry

Pegcetacoplan injection for geographic atrophy (GA) led to fewer absolute scotomatous points, compared with eyes that had delayed treatment, over 36 months, suggesting the efficacy of the therapy for preserving visual function.

In this clip, Garg explains microperimetry as a visual function endpoint after 36 months of pegcetacoplan treatment in GALE.

#2 Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort

Interim results from the Phase 2 PRISM population extension cohort demonstrated the efficacy and tolerability of 4D-150 gene therapy for nAMD, showing a reduction in the mean annualized anti-vascular endothelial growth factor (VEGF) injection rate by up to 91%.

In this clip, Maturi summarizes interim data from the Phase 2 PRISM population extension cohort evaluating 4D-150 for nAMD.

#1 Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X

Four-year data from the RHONE-X extension study showed the trial met its primary endpoint, demonstrating strong tolerability in treating diabetic macular edema (DME) for up to 4 years, as more than 90% of patients experienced an absence of DME.

In this clip, Khanani focuses on patient reaction to faricimab in clinical practice.

Visit our conference page here for more coverage from ASRS 2024.